Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

MBCProject_0209_T1_RNA

— · C

246a8796-0ddc-5deb-9d51-4b32683ca7ea

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
C
subtype
C

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • ANGIOGENESIS+0.610
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.550
  • COAGULATION+0.490
  • TGF_BETA_SIGNALING+0.430
  • ADIPOGENESIS+0.420
  • REACTIVE_OXYGEN_SPECIES_PATHWAY+0.420
  • XENOBIOTIC_METABOLISM+0.370
  • HEDGEHOG_SIGNALING+0.360
  • PROTEIN_SECRETION+0.360
  • ANDROGEN_RESPONSE+0.340

Top 10 suppressed

  • INTERFERON_ALPHA_RESPONSE-0.350
  • INTERFERON_GAMMA_RESPONSE-0.170
  • HEME_METABOLISM-0.160
  • KRAS_SIGNALING_DN-0.130
  • MYC_TARGETS_V2-0.110
  • DNA_REPAIR-0.100
  • MITOTIC_SPINDLE-0.100
  • WNT_BETA_CATENIN_SIGNALING-0.040
  • E2F_TARGETS+0.010
  • ESTROGEN_RESPONSE_EARLY+0.010

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

8 twins match this tumor's tissue · 2 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1BSR_06_0059_A2_S99
breast-umap@18
—F0.873
2TCGA-18-3417-01A-01R-1443-07
lung-landscapes@6
—cohortSQ10.844
3SRR1313160
breast-umap@18
—E0.837
420040045.TNBC
breast-umap@18
—F0.823
5SRR1313161
breast-umap@18
—C0.805
6EPT0508
medullo-epn-umap@date-based
EPNPosterior Fossa EPN0.793
720060039.TNBC
breast-umap@18
—C0.792
8TCGA-BH-A0AY-01A-21R-A00Z-07
breast-umap@18
—A0.792
9TCGA-BH-A0DZ-01A-11R-A00Z-07
breast-umap@18
—C0.786
10BS_30VC3R2Q
brain-umap@2
Diffuse intrinsic pontine glioma—0.783

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 42 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
ANGIOGENESIS0.610Remibrutinib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.550Inavolisib— uncovered
COAGULATION0.490Binimetinib— uncovered
TGF_BETA_SIGNALING0.430Inavolisib— uncovered
ADIPOGENESIS0.420Inavolisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.420Inavolisib— uncovered
XENOBIOTIC_METABOLISM0.370Inavolisib— uncovered
HEDGEHOG_SIGNALING0.360Inavolisib— uncovered
PROTEIN_SECRETION0.360Remibrutinib— uncovered
ANDROGEN_RESPONSE0.340Inavolisib— uncovered
FATTY_ACID_METABOLISM0.340Inavolisib— uncovered
UV_RESPONSE_DN0.340Inavolisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.330Remibrutinib— uncovered
MTORC1_SIGNALING0.330Inavolisib— uncovered
COMPLEMENT0.320Inavolisib— uncovered
KRAS_SIGNALING_UP0.310Inavolisib— uncovered
NOTCH_SIGNALING0.310Inavolisib— uncovered
APOPTOSIS0.300Idelalisib— uncovered
GLYCOLYSIS0.280Inavolisib— uncovered
HYPOXIA0.280Idelalisib— uncovered